NYSE · BSX

Boston Scientific Corp.

$46.61 +$2.36 (+5.33%) 1D Market open
Session Pulse Regular session chatter is louder than usual 1 mentions on Mon 1 SEC filing since Mon close 8-K its sector ranked 5/11 this week Full pulse →

Key Metrics

$65.77B
Market cap
18.48×
P/E · TTM
$20.61B
Revenue · TTM
$3.56B
Net income
EPS · TTM $2.38
Dividend yield
Free cash flow $3.48B
Beta · 1Y 0.12
EBITDA · TTM $5.14B
Gross margin 69.2%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 27
    A material event was filed (Form 8-K).

    8-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)

    RECEIPT: SEC FORM 8-K, TIMESTAMPED
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 14
    From its Jan 30 high, the share price fell 54%.

    Peak close $93.53 on Jan 30; trough close $42.63 on Jul 14. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -54%
  • May 27
    The stock moved -12.5% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 27
  • Feb 4
    The stock moved -17.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 4

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$65.77B
Enterprise value$75.35B
Shares outstanding1.5B
52-wk range$42.20 – $109.50
Avg volume · 20D8.7M
Net cash −$9.58B
Book value / share$17.32
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNYSE
About Boston Scientific Corp.
IPO dateMay 18, 1992
Employees59000

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E18.48
P/S3.19
P/FCF18.93
EV/EBITDA14.67
EV/Sales3.66
Graham №$30.48

Profitability

Gross 69.2%
Operating 18.2%
Net 17.3%
FCF 16.9%
ROE / ROIC 14.9% · 10.0%

Financial Health

Current ratio1.90
Quick ratio1.22
Debt / equity0.43
Debt / EBITDA 2.15
Net cash −$9.58B
Working capital$4.11B

Cash Flow · TTM

Operating CF $4.34B
Capex −$866.00M
Free cash flow $3.48B
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

7 / 9
Strong fundamentals · 7 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

$30.48 vs $45.51
Trades 1.5× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings